The role of extended infusion β-lactams in the treatment of bloodstream infections in patients with liver cirrhosis

References

• Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet. 2006;367(9504):52–56.
   PubMed Web of Science ®Google Scholar
• Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56(Suppl 1):S1–12.
   PubMedGoogle Scholar
• Fernandez J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatol. 2012;55(5):1551–1561.
   PubMed Web of Science ®Google Scholar
• Pant C, Olyaee M, Gilroy R, et al. Emergency department visits related to cirrhosis: a retrospective study of the nationwide emergency department sample 2006 to 2011. Medicine. 2015;94(1):e308.
   PubMed Web of Science ®Google Scholar
• Piano S, Morando F, Carretta G, et al. Predictors of early readmission in patients with cirrhosis after the resolution of bacterial infections. Am J Gastroenterol. 2017;112(10):1575–1583.
   PubMed Web of Science ®Google Scholar
• Sola E, Fernandez J, Gines P. Acute-on-chronic liver failure: the role of precipitating illness. Semin Liver Dis. 2016;36(2):117–122.
   PubMed Web of Science ®Google Scholar
• Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterol. 2013;144(7):1426–1437, 1437 e1421–1429.
   PubMed Web of Science ®Google Scholar
• Fernandez J, Acevedo J, Wiest R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2017.
   Web of Science ®Google Scholar
• Shalimar, Rout G, Jadaun SS, et al. Prevalence, predictors and impact of bacterial infection in acute on chronic liver failure patients. Dig Liver Dis. 2018 May 28. pii: S1590-8658(18)30757-6. doi: 10.1016/j.dld.2018.05.013. [Epub ahead of print].
   Google Scholar
• Bellot P, Frances R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int: Off J Int Assoc Study Liver. 2013;33(1):31–39.
   PubMed Web of Science ®Google Scholar
• Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61(6):1385–1396.
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Ong JP, Younossi ZM, et al. Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. Chest. 2001;119(5):1489–1497.
   PubMed Web of Science ®Google Scholar
• Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60(6):1310–1324.
   PubMed Web of Science ®Google Scholar
• Merli M, Lucidi C, Di Gregorio V, et al. The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey. PloS one. 2015;10(5):e0127448.
   PubMed Web of Science ®Google Scholar
• Bartoletti M, Giannella M, Lewis R, et al. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2018;24(5): 546 e541-546 e548.
   Google Scholar
• Fernandez J, Bert F, Nicolas-Chanoine MH. The challenges of multi-drug-resistance in hepatology. Journal of hepatology. 2016;65(5): 1043-1054.
   Google Scholar
• Arvaniti V, D’Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterol. 2010;139(4):1246–1256, 1256 e1241–1245.
   PubMed Web of Science ®Google Scholar
• Dionigi E, Garcovich M, Borzio M, et al. Bacterial infections change natural history of cirrhosis irrespective of liver disease severity. Am J Gastroenterol. 2017;112(4):588–596.
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Scotto R, et al. Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage. Eur J Intern Med. 2017;46:e45–e47.
   PubMed Web of Science ®Google Scholar
• Leber B, Spindelboeck W, Stadlbauer V. Infectious complications of acute and chronic liver disease. Semin Respir Crit Care Med. 2012;33(1):80–95.
   PubMed Web of Science ®Google Scholar
• Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatol. 2002;35(1):140–148.
   PubMed Web of Science ®Google Scholar
• Sargenti K, Prytz H, Strand A, et al. Healthcare-associated and nosocomial bacterial infections in cirrhosis: predictors and impact on outcome. Liver Int: Off J Int Assoc Study Liver. 2015;35(2):391–400.
   PubMed Web of Science ®Google Scholar
• Fiuza C, Salcedo M, Clemente G, et al. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis. 2000;182(2):526–533.
   PubMed Web of Science ®Google Scholar
• Gomez F, Ruiz P, Schreiber AD. Impaired function of macrophage Fc gamma receptors and bacterial infection in alcoholic cirrhosis. N Engl J Med. 1994;331(17):1122–1128.
   PubMed Web of Science ®Google Scholar
• Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2011;9(9):727–738.
   PubMed Web of Science ®Google Scholar
• Tritto G, Bechlis Z, Stadlbauer V, et al. Evidence of neutrophil functional defect despite inflammation in stable cirrhosis. J Hepatol. 2011;55(3):574–581.
   PubMed Web of Science ®Google Scholar
• Thulstrup AM, Sorensen HT, Schonheyder HC, et al. Population-based study of the risk and short-term prognosis for bacteremia in patients with liver cirrhosis. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2000;31(6):1357–1361.
   PubMed Web of Science ®Google Scholar
• Bartoletti M, Baldassarre M, Domenicali M, et al. Outcome of bacterial infections complicated or not by acute-on-chronic liver failure in patients with cirrhosis admitted to hospital for acute decompensation. EASL-International Liver Congress April 11–15, 2018; Paris
   Google Scholar
• Ortega M, Almela M, Soriano A, et al. Bloodstream infections among human immunodeficiency virus-infected adult patients: epidemiology and risk factors for mortality. Eur J Clin Microbiol Infect Dis. 2008;27(10):969–976.
   PubMed Web of Science ®Google Scholar
• Chen SY, Tsai CL, Lin CH, et al. Impact of liver cirrhosis on mortality in patients with community-acquired bacteremia. Diagn Microbiol Infect Dis. 2009;64(2):124–130.
   PubMed Web of Science ®Google Scholar
• Chang TY, Lee CH, Liu JW. Clinical characteristics and risk factors for fatality in patients with bloodstream infections caused by glucose non-fermenting gram-negative Bacilli. J Microbiol Immunol Infect. 2010;43(3):233–239.
   PubMedGoogle Scholar
• Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Predictive scoring model of mortality in Gram-negative bloodstream infection. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2013;19(10): 948-954
   Google Scholar
• Nelson AN, Justo JA, Bookstaver PB, et al. Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections. Infection. 2017;45(5):613–620.
   PubMed Web of Science ®Google Scholar
• Giannella M, Pascale R, Toschi A, et al. Treatment duration for Escherichia coli bloodstream infection and outcomes: retrospective single-centre study. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2018;24(10): 1077-1083..
   Google Scholar
• Bartoletti M, Giannella M, Lewis RE, et al. Bloodstream infections in patients with liver cirrhosis. Virulence. 2016;7(3):309–319.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Syed A, Rupp ME, et al. Is bacteremic sepsis associated with higher mortality in transplant recipients than in nontransplant patients? A matched case-control propensity-adjusted study. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2015;60(2):216–222.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Lopez-Prieto MD, Portillo MM, et al. Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis. 2010;16(9):1408–1413.
   PubMed Web of Science ®Google Scholar
• Bartoletti M, Vandi G, Furii F, et al. Management of immunosuppressive therapy in liver transplant recipients who develop bloodstream infection. Transpl Infect Dis. 2018 May 29:e12930. doi: 10.1111/tid.12930.
   Google Scholar
• Zhao H, Gu X, Zhao R, et al. Evaluation of prognostic scoring systems in liver cirrhosis patients with bloodstream infection. Medicine. 2017;96(50):e8844.
   PubMed Web of Science ®Google Scholar
• Campillo B, Richardet JP, Kheo T, et al. Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2002;35(1):1–10.
   PubMed Web of Science ®Google Scholar
• Karvellas CJ, Pink F, McPhail M, et al. Bacteremia, acute physiology and chronic health evaluation II and modified end stage liver disease are independent predictors of mortality in critically ill nontransplanted patients with acute on chronic liver failure. Crit Care Med. 2010;38(1):121–126.
   PubMed Web of Science ®Google Scholar
• Park H, Jang KJ, Jang W, et al. Appropriate empirical antibiotic use and 30-d mortality in cirrhotic patients with bacteremia. World J Gastroenterol. 2015;21(12):3587–3592.
   PubMed Web of Science ®Google Scholar
• Brandolini M, Corbella M, De Silvestri A, et al. Epidemiological characteristics of bloodstream infections in patients with different degrees of liver disease. Infection. 2015.
   PubMedGoogle Scholar
• Bartoletti M, Giannella M, Caraceni P, et al. Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. J Hepatol. 2014;61(1):51–58.
   PubMed Web of Science ®Google Scholar
• Hsieh CC, Lee CC, Chan TY, et al. Clinical features and impact of empirical therapy in cirrhotic adults with community-onset bacteremia. Am J Emerg Med. 2015;33(2):222–228.
   PubMed Web of Science ®Google Scholar
• Fiore M, Maraolo AE, Gentile I, et al. Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: a systematic review. World J Gastroenterol. 2017;23(25):4654–4660.
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock–does the dose matter? Crit Care. 2009;13(3):214.
   PubMed Web of Science ®Google Scholar
• Westphal JF, Jehl F, Vetter D. Pharmacological, toxicologic, and microbiological considerations in the choice of initial antibiotic therapy for serious infections in patients with cirrhosis of the liver. Clin Infect Dis: Off Publ Infect Dis Soc Am. 1994;18(3):324–335.
   PubMed Web of Science ®Google Scholar
• Joynt GM, Lipman J, Gomersall CD, et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother. 2001;47(4):421–429.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840–851. quiz 859.
   PubMed Web of Science ®Google Scholar
• Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient–concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11.
   PubMed Web of Science ®Google Scholar
• Henriksen JH, Kiszka-Kanowitz M, Bendtsen F. Review article: volume expansion in patients with cirrhosis. Aliment Pharmacol Ther. 2002;16(Suppl 5):12–23.
   PubMedGoogle Scholar
• Hosein S, Udy AA, Lipman J. Physiological changes in the critically ill patient with sepsis. Curr Pharm Biotechnol. 2011;12(12):1991–1995.
   PubMed Web of Science ®Google Scholar
• Vrhovac B, Sarapa N, Bakran I, et al. Pharmacokinetic changes in patients with oedema. Clin Pharmacokinet. 1995;28(5):405–418.
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–1161.
   PubMed Web of Science ®Google Scholar
• Lheureux O, Trepo E, Hites M, et al. Serum beta-lactam concentrations in critically ill patients with cirrhosis: a matched case-control study. Liver Int: Off J Int Assoc Study Liver. 2016;36(7):1002–1010.
   PubMed Web of Science ®Google Scholar
• Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279–1290.
   PubMed Web of Science ®Google Scholar
• Proulx NL, Akbari A, Garg AX, et al. Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis. Nephrol, Dialysis, Transplantation: off Publ Eur Dial Transpl Assoc Eur Ren Assoc. 2005;20(8):1617–1622.
   Google Scholar
• EASL Clinical Practice. Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460.
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis: Off Publ Infect Dis Soc Am. 1998;26(1): 1–10. quiz 11–12.
   PubMed Web of Science ®Google Scholar
• Moriyama B, Henning SA, Neuhauser MM, et al. Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria. Ann Pharmacother. 2009;43(7):1324–1337.
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Dulhunty JM, Bellomo R, et al. Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care. 2012;2(1):37.
   PubMedGoogle Scholar
• Mouton JW, Den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994;38(5):931–936.
   PubMed Web of Science ®Google Scholar
• Rafati MR, Rouini MR, Mojtahedzadeh M, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents. 2006;28(2):122–127.
   PubMed Web of Science ®Google Scholar
• Bao H, Lv Y, Wang D, et al. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial. Eur J Clin Microbiol Infect Dis: Off Publ Eu Soc Clin Microbiol. 2017;36(3):459–466.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Voulgaris GL, Maliaros A, et al. Prolonged versus short-term intravenous infusion of antipseudomonal beta-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis. 2018;18(1):108–120.
   PubMed Web of Science ®Google Scholar
• Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2013;56(2):236–244.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Davis JS, et al. Continuous versus intermittent beta-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194(6):681–691.
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016;42(10):1535–1545.
   PubMed Web of Science ®Google Scholar
• Dulhunty JM, Roberts JA, Davis JS, et al. A multicenter randomized trial of continuous versus intermittent beta-lactam infusion in severe sepsis. Am J Respir Crit Care Med. 2015;192(11):1298–1305.
   PubMed Web of Science ®Google Scholar
• Lau WK, Mercer D, Itani KM, et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2006;50(11):3556–3561.
   PubMed Web of Science ®Google Scholar
• Cotrina-Luque J, Gil-Navarro MV, Acosta-Garcia H, et al. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa. Int J Clin Pharm. 2016;38(1):70–79.
   PubMed Web of Science ®Google Scholar
• Bartoletti M, Giannella M, Tedeschi S, et al. Opportunistic infections in end stage liver disease. Infect Dis Rep. 2018;10(1):7621.
   PubMed Web of Science ®Google Scholar
• Bartoletti M, Giannella M, Lewis R, et al. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis. 2018;24(5):546, e541–546, e548.
   Web of Science ®Google Scholar
• Moriyama B, Henning SA, Childs R, et al. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann Pharmacother. 2010;44(5):929–935.
   PubMed Web of Science ®Google Scholar
• Piano S, Bartoletti M, Tonon M, et al. Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. Gut. 2017.
   PubMed Web of Science ®Google Scholar
• Carlier M, Verstraete AG, De Waele JJ, et al. Stability of amoxicillin and amoxicillin/clavulanic acid reconstituted in isotonic saline. J Chemother. 2017;29(1):54–56.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498–509.
   PubMed Web of Science ®Google Scholar
• Fuchs A, Csajka C, Thoma Y, et al. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet. 2013;52(1):9–22.
   PubMed Web of Science ®Google Scholar